Become a MemberHomeJoin Mailing ListContact Us

Industry Supported Symposia (ISS)

 

Industry Supported Symposia will be offered to conference attendees free of charge. These will be sponsored by a variety of companies. Topics have been approved by the Program Committee and are intended to complement the Plenary Sessions, Mini Symposia and Educational Sessions of the Conference.

 

Please click on the session titles for futher program information.

 

  Sunday, October 27
  12:00 - 13:30

ISS supported by Boehringer Ingelheim: Questions in the Treatment of NSCLC: Targeting Angiogenesis

 
       
  14:00 - 15:30

ISS supported by AstraZeneca: Future Concepts in EGFR Mutation-Positive Advanced NSCLC

 
       
  16:00 - 17:30

ISS supported by Pfizer: Preparing for Tomorrow: Molecular Diagnostics and the Changing NSCLC Landscape

 
       
  Monday, October 28
  07:00 - 08:00

ISS supported by Celgene: Tackling the Challenges of Squamous Cell NSCLC Patients

 

ISS supported by Myriad: Validation of a 46-Gene Expression Signature in Early-Stage Non-Small-Cell Lung Cancer

 

ISS supported by Boehringer Ingelheim: Let's Discuss: Optimising Treatment of Advanced NSCLC

 

ISS supported by Peregrine Pharmaceuticals: Immune Checkpoints in the Tumor Environment: Novel Targets and the Clinical Promise of Combined Immunotherapies

 
       
  12:15 - 13:45

ISS supported by Lilly Oncology: The Continuous Evolution of Treatment in Advanced NSCLC

     
  18:00 - 19:30

ISS supported by Roche: Hitting the High Notes in NSCLC Therapy

     
  Tuesday, October 29
  07:00 - 08:00

ISS supported by IASLC Radiotherapy Group: What is the Appropriate Patient Population for SBRT? (Simultaneous translation English >< Mandarin will be provided)

 

ISS supported by Novartis: Up Close and Personal: Future Targeted Strategies in NSCLC

 

 
       
  12:15 - 13:45

ISS supported by Boehringer Ingelheim: Questions in the Treatment of NSCLC: Focus on EGFR Mutation-Positive NSCLC

     
  18:00 - 19:30

ISS supported by Roche: New Horizons in First-Line NSCLC Therapy

     
  Wednesday, October 30
  07:00 - 08:00

ISS supported by IASLC Radiotherapy Group: What is the Appropriate Patient Population for IGRT? (Simultaneous translation English >< Mandarin will be provided)

 
       
  12:15 - 13:45

ISS supported by BMS: Perspectives in Lung Cancer: Is Immuno-Oncology the New Treatment Paradigm?